Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entrada Therapeutics filings document a clinical-stage biopharmaceutical issuer developing genetic medicines that engage intracellular targets. Recent Form 8-K reports furnish quarterly and annual financial results, cash and marketable-securities updates, and corporate updates related to its Duchenne muscular dystrophy franchise, ocular disease pipeline and partnered VX-670 program for myotonic dystrophy type 1.
Proxy materials describe annual meeting matters, including director elections, auditor ratification and amendments to the company’s stock option and employee stock purchase plans. The filings also identify TRDA common stock listed on The Nasdaq Global Market, emerging growth company status, Regulation FD disclosures and governance matters tied to equity compensation and stockholder voting.
Entrada Therapeutics director and 10% owner Kush Parmar received a grant of stock options covering 19,000 shares of Common Stock. The options have an exercise price of $5.97 per share and expire on June 10, 2036. These options vest on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders.
Entrada Therapeutics director Peter S. Kim received a grant of stock options covering 19,000 shares of common stock. The options have an exercise price of $5.97 per share and expire on June 10, 2036. According to the terms, they vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders.
Entrada Therapeutics director Gina Chapman received a grant of stock options to buy 19,000 shares of common stock at an exercise price of $5.97 per share. These options vest on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders and expire on June 10, 2036.
Entrada Therapeutics director Radhakrishnan Maha received a grant of 19,000 stock options. Each option allows the purchase of one share of common stock at an exercise price of $5.97 per share and was granted at no cost.
The options vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or Entrada’s next annual meeting of stockholders, and expire on June 10, 2036. After this grant, Maha holds 19,000 stock options directly.
Entrada Therapeutics director Mary Thistle received a stock option grant covering 19,000 shares of common stock. The option has an exercise price of $5.97 per share and expires on June 10, 2036. According to the terms, the award vests on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders. This is a compensation-related grant rather than an open-market trade.
Entrada Therapeutics director Bernhardt G. Zeiher received a grant of stock options covering 19,000 shares of common stock. The options have an exercise price of $5.97 per share and expire on June 10, 2036. They vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders.
Entrada Therapeutics reported the results of its 2026 annual stockholder meeting, held virtually on June 10, 2026. Stockholders approved amendments to the company’s 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan to change the evergreen formulas so that outstanding pre-funded warrants are counted in determining annual share pool increases.
Two Class II directors, Peter S. Kim, Ph.D. and Bernhardt Zeiher, M.D., were re-elected to the board. Stockholders also ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026. The meeting achieved a quorum, with 33,190,234 of 38,820,616 common shares entitled to vote represented in person or by proxy.
Entrada Therapeutics director-related trust buys shares. A revocable living trust associated with director Bernhardt G. Zeiher purchased 5,000 shares of Entrada Therapeutics common stock in an open-market transaction at a weighted average price of $5.8632 per share, with trade prices ranging from $5.86 to $6.00. Following the purchase, the trust holds 5,000 shares indirectly, and Dr. Zeiher disclaims beneficial ownership beyond any pecuniary interest.
Entrada Therapeutics, Inc. furnished a current report to share an updated corporate presentation with investors, analysts and other stakeholders. The refreshed presentation, dated May 2026, is attached as Exhibit 99.1 and is incorporated by reference in this report.
The disclosure is made under Regulation FD, which is designed to ensure fair and equal access to important company information. The material is expressly described as furnished, not filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings unless specifically referenced.
Entrada Therapeutics reported a larger loss for the quarter ended March 31, 2026 as it invested heavily in its genetic medicines pipeline. Collaboration revenue fell to $0.9 million from $20.6 million a year earlier, mainly because work under its Vertex partnership wound down.
Research and development expenses were $33.1 million and general and administrative costs were $10.1 million, leading to a net loss of $39.7 million, or $0.95 per share, versus a $17.3 million loss, or $0.42 per share, in the prior-year period.
Cash, cash equivalents and marketable securities totaled $254.9 million, which the company believes can fund operations into the third quarter of 2027. Entrada is advancing multiple Duchenne muscular dystrophy programs, including ENTR-601-44 and ENTR-601-45, and its partnered DM1 candidate VX-670 with Vertex, with several data readouts expected in 2026.
Entrada Therapeutics reported a larger loss for the quarter ended March 31, 2026 as it invested heavily in its genetic medicines pipeline. Collaboration revenue fell to $0.9 million from $20.6 million a year earlier, mainly because work under its Vertex partnership wound down.
Research and development expenses were $33.1 million and general and administrative costs were $10.1 million, leading to a net loss of $39.7 million, or $0.95 per share, versus a $17.3 million loss, or $0.42 per share, in the prior-year period.
Cash, cash equivalents and marketable securities totaled $254.9 million, which the company believes can fund operations into the third quarter of 2027. Entrada is advancing multiple Duchenne muscular dystrophy programs, including ENTR-601-44 and ENTR-601-45, and its partnered DM1 candidate VX-670 with Vertex, with several data readouts expected in 2026.